Baseimmune, a London-based biotech leveraging deep learning AI to predict pathogen mutations for vaccine development, has raised $11.3M (approximately €10.40M) in a Series A funding round. The investment was led by new investors MSD Global Health Innovation Fund and IQ Capital, with participation from existing backers such as Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Baseimmune is at the forefront of creating the next generation of universal vaccines against a wide range of human and animal health threats, from COVID to malaria and African Swine Fever. “By using a computational platform and innovative AI prediction algorithm, Baseimmune is pioneering the next generation of universal vaccines,” said Alex Wilson, Partner at IQ Capital.
Advertisement
Utilizing Capital for Vaccine Candidate Development
The funding will accelerate the development of Baseimmune’s three vaccine candidates currently in preclinical development for African swine fever, coronavirus, and malaria. Additionally, the investment will support the advancement of Baseimmune’s technology, team expansion, and the acceleration of new vaccine programs.
Revolutionizing Vaccine Design with AI
Founded in 2019 by Joshua Blight and Ariane Gomes, alongside software engineer Phillip Kemlo, Baseimmune employs an antigen design platform that combines genomic, epidemiological, immunological, clinical, and evolutionary data. This approach crafts entirely new synthetic antigenic proteins, targeting pathogen components for a robust protective immune response.
Baseimmune’s technology decodes pathogen evolution, expediting the design of cross-protective vaccines. Leveraging big data and a design algorithm, the process accelerates vaccine development, resulting in antigen designs compatible with various vaccine technologies, including mRNA, DNA, and viral vectors. This creates universal “future-proof” vaccines effective against current and potential future variants.
A Vision for Future Pandemic Readiness
“We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital,” stated Joshua Blight, CEO and co-founder of Baseimmune. “This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens.”
With this Series A funding, the BioTech Company is more excited than ever about the possibilities and remains focused on its commitment to disrupting the future of pandemic readiness, aiming to provide mutation-proof vaccines for a safer global health landscape.
